ArticleDermatology and therapy2025
Treat-to-Target in Clinical Practice: Evaluating Real-World Achievement Rates Against Consensus Guidelines for Atopic Dermatitis.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis: A Retrospective Analysis of Outcomes from Real-World Canadian Practice.Dermatology and therapy · 2026Article
- Long-Term Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A Real-World, Retrospective Study.Dermatology and therapy · 2026Article
- Hydrocolloid versus Liquid Dressings for Incontinence-Associated Dermatitis: A Clinical Evaluation in Critically Ill Patients.Clinical, cosmetic and investigational dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionTreat-to-target (T2T) strategies have been adopted in atopic dermatitis (AD) management, which defines specific moderate/acceptable and optimal targets for reducing disease severity. However, real-world evidence on the achievement rates of these targets remains limited.
methodsThis prospective observational study enrolled patients with moderate-to-severe AD without treatment protocol modifications. Disease severity was longitudinally assessed using 5-point Patient Global Impression of Severity (PGIS-5), Peak Pruritus Numerical Rating Scale (pp-NRS), Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), Body Surface Area (BSA), Eczema Area and Severity Index (EASI), and Scoring Atopic Dermatitis (SCORAD) at baseline and weeks 2, 4, 8, and 16. Treatment responses were compared against two established T2T frameworks: the T2T consensus (de Bruin-Weller et al.) and Aiming High in Eczema/Atopic Dermatitis (AHEAD) recommendations (Silverberg et al.). Target feasibility was evaluated through achievement rates, with thresholds calibrated to balance timely clinical response.
resultsSixty-one patients with moderate-to-severe AD were enrolled. All outcomes measured showed significant improvement over the 16-week observation period. SCORAD50, EASI50, pp-NRS reduction ≥ 3/4, and DLQI reduction ≥ 4 demonstrated appropriate moderate target feasibility. SCORAD75, EASI75/90, pp-NRS ≤ 1, BSA ≤ 2%, and DLQI 0/1 were suitable as optimal targets. Percentage improvements of EASI and SCORAD were more reliable than absolute values. Current targets for PGIS-5 (reduction ≥ 1), POEM (reduction ≥ 4), and BSA (50% improvement) in the moderate category and PGIS-5 ≤ 2 and POEM ≤ 7 in the optimal category may require stricter criteria.
conclusionOur finding reflects the real-world achievement rate of the current T2T consensus, suggesting that higher thresholds may be warranted in future refinements of T2T strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.